The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|July 1, 2024
- Pharmaceutical Technology, July 2024
- Volume 48
- Issue 7
- Pages: 8
CO2 Incubators
Author(s)Pharmaceutical Technology Editors
The VIOS family of incubators are known for optimal cell growth conditions and minimal contamination risk.
Thermo Fisher Scientific has introduced the Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators, first-of-their-kind CO2 incubators designed for integration into automated and modular laboratories to support future implementation of automated cell therapy workflows. The VIOS family of incubators are known for optimal cell growth conditions and minimal contamination risk. The new Heracell VIOS 250i AxD incubators have the added innovation of a patent-pending automated door control, allowing them to open automatically when integrated into a centralized lab automation platform. The added innovation allows for vessel loading and unloading through robotic control and supports continuous cell therapy production processes. Other important features include in-chamber high efficiency particulate air filtration; Thermo Scientific THRIVE active airflow for homogeneous culturing conditions throughout the incubator chamber; and the Thermo Scientific Steri-Run Cycle, which is capable of a 12-log sterility assurance level, eliminating more than one million biological indicators for both dry heat sterilization and autoclave sterilization in half the lethal time used in production models.
Articles in this issue
over 2 years ago
Biobetter Developmentover 2 years ago
Taking Stock of a Maturing CGT Sectorover 2 years ago
QRM, Knowledge Management, and the Importance of ICH Q9(R1)over 2 years ago
The Rising Iceberg of Lyophilized Innovationsover 2 years ago
Advancing Analytical Testing Techniquesover 2 years ago
The Importance of HCP Monitoringover 2 years ago
Publisher's Note: With Age Comes Wisdomover 2 years ago
Post-Warning Letter Interaction with FDAover 2 years ago
Flexible Inline High Shear Mixer with Built-in WorkbenchRelated to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.